Association for Accessible Medicines files comments with FTC addressing buyer consolidation and anti-competitive tactics
“Today AAM is calling on the FTC and other federal agencies to take action against anti-competitive practices and consolidation of large-scale buying groups that are threatening the future supply of affordable generic and biosimilar medicines in the U.S. FDA-approved generic medicines have saved patients, taxpayers and other payers $1.67 trillion over the past decade. But patient access and savings is now at risk due to gamesmanship of some brand-name drug companies as well as intense supply chain consolidation. The FTC and other agencies must formally investigate these practices and take action to ensure the continued supply of generic and biosimilar medicines for patients.”
Attribution: Chester “Chip” Davis, Jr., President and CEO, Association for Accessible Medicines
MEDIA CONTACT:
Rachel Schwartz
202.249.7147 (o)
202.251.8881 (c)